Emergent Comorbid Events in First Year of Immunomodulatory Treatment in Adults With Generalized Myasthenia Gravis treated in a Neurology Clinic: A Retrospective Review
Keywords:Corticosteroids, Immunomodulators, Myasthenia Gravis, Pyridostigmine
Background: Current treatments for myasthenia gravis, including immunomodulatory therapies, are associated with significant comorbid events.
Method: Retrospective chart review of all adults diagnosed with generalized myasthenia gravis in our clinic over 5 years to evaluate potential associations between treatment regimens and emergent comorbid events according to system organ class. Comorbid events were categorized by affected system organ class as endocrine, neuropsychiatric, musculoskeletal, gastrointestinal, pulmonary, cardiovascular, urologic, infectious, and hematologic. MG treatment regimens at the latest available date during the 1-year follow-up were categorized by corticosteroid use and further stratified by medication class and combination therapy.
Result: A total of 68 patients were included in the analysis (corticosteroid group, n = 43; non-corticosteroid group, n = 25). We found no significant differences in the frequencies of comorbid events between patients whose regimens included corticosteroids and patients with corticosteroid-free regimens. Patients who received pyridostigmine, high-dose corticosteroids, and corticosteroid-sparing agents in combination experienced higher incidences of emergent endocrine and neuropsychiatric events than those who received other corticosteroid-containing treatments.
Conclusion: Polypharmacy that included high-dose corticosteroids was associated with a greater incidence of new endocrine and neuropsychiatric comorbid events within 1 year of diagnosis
Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570-2581.
Howard Jr JF. Clinical overview of MG. Myasthenia Gravis Foundation of America; 2015. Available at: https://myasthenia.org/For-Professionals/Clinical-Overview-of-MG. Accessed June 29, 2020.
Farmakidis C, Pasnoor M, Dimachkie MM, et al. Treatment of myasthenia gravis. Neurol Clin. 2018;36:311-337.
Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60:707-715.
Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7:e013278.
Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893-902.
Bacci ED, Coyne KS, Poon JL, et al. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19:335.
Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.
Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43:428-435.
Howard Jr JF. Electrodiagnosis of disorders of neuromuscular transmission. Phys Med Rehabil Clin N Am. 2013;24:169-192.
Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.
Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778-1783.
Rozsa C, Lovas G, Fornadi L, et al. Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients. Eur J Neurol. 2006;13:947-952.
Gilhus NE, Nacu A, Andersen JB, et al. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22:17-23.
Gilhus NE, Romi F, Hong Y, et al. Myasthenia gravis and infectious disease. J Neurol. 2018;265:1251-1258.
Dunand M, Botez SA, Borruat FX, et al. Unsatisfactory outcomes in myasthenia gravis: influence by care providers. J Neurol. 2010;257:338-343.
How to Cite
Copyright (c) 2023 Nakul Katyal MD, Brian Blankenship MD, Naureen Narula MD, Eric Grisham BAS, Raghav Govindarajan MD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.